In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...

AstraZeneca PLC (LON:AZN – Get Free Report) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £114.82 ($144.52) and traded as high as ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

AstraZeneca (NASDAQ:AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of muscle-invasive bladder cancer, or MIBC. The analysis showed that ...